AI-Generated Summary

President Trump announced a deal with Pfizer to lower drug prices for Medicaid and patients, with new medicines priced at parity with other countries in exchange for tariff exemptions, aiming to secure cheaper prescription medicines. This marks a significant government initiative to reduce U.S. prescription medicine costs. Additionally, WHO members are reportedly prioritizing scientific and academic advice over pharmaceutical industry lobbyists for a new pandemic agreement.

In a nutshell

This development signals increased government intervention in drug pricing, potentially influencing future pharmaceutical market access strategies and setting precedents for other drugmakers. The WHO's move underscores a global drive for independent, evidence-based health policy, which could reshape international regulatory landscapes.

Source: STAT